Holen Sie sich die Stockscreener-App
0.3692
1.48%
0.0054
Schlusskurs vom Vortag:
$0.3638
Offen:
$0.3701
24-Stunden-Volumen:
1.19M
Relative Volume:
0.55
Marktkapitalisierung:
$50.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.76M
KGV:
-0.2735
EPS:
-1.35
Netto-Cashflow:
$-55.17M
1W Leistung:
+4.50%
1M Leistung:
-9.27%
6M Leistung:
-71.16%
1J Leistung:
-91.80%
1-Tages-Spanne:
$0.365
$0.389
1-Wochen-Bereich:
$0.345
$0.389
52-Wochen-Spanne:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Firmenname
Applied Therapeutics Inc
Sektor
Branche
Telefon
212-220-9226
Adresse
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Vergleichen Sie APLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.3692 | 50.02M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-23 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-31 | Eingeleitet | William Blair | Outperform |
| 2024-03-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-22 | Eingeleitet | Leerink Partners | Outperform |
| 2022-01-04 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-27 | Herabstufung | Goldman | Neutral → Sell |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-04-22 | Eingeleitet | Goldman | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-06-10 | Eingeleitet | Citigroup | Buy |
| 2019-06-10 | Eingeleitet | Cowen | Outperform |
| 2019-06-10 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Applied Therapeutics Inc Aktie (APLT) Neueste Nachrichten
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
Millennium Management LLC Grows Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire
BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) PT at $6.10 - Defense World
Applied Therapeutics’ (APLT) “Sector Perform” Rating Reiterated at Royal Bank of Canada - Defense World
APLT: RBC Capital Reiterates Sector Perform Rating, Price Target Maintained | APLT Stock News - GuruFocus
APLT Reports Financial Position and Advances in Govorestat Resea - GuruFocus
Applied Therapeutics Reports First Quarter 2025 Financial Results | APLT Stock News - GuruFocus
Applied Therapeutics, Inc. SEC 10-Q Report - TradingView
Barclays PLC Sells 27,997 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Alyeska Investment Group L.P. Boosts Stock Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky about Pending Class ActionAPLT - ACCESS Newswire
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Finanzdaten der Applied Therapeutics Inc-Aktie (APLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Applied Therapeutics Inc-Aktie (APLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):